P Garcia-Peris1, C Velasco1, M Hernandez2, M A Lozano3, L Paron1, C de la Cuerda1, I Breton1, M Camblor1, F Guarner4. 1. Nutrition Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 2. Department of Biotechnology, Polytechnic University of Valencia, Valencia, Spain. 3. Radiotherapy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. 4. Digestive System Research Unit, Hospital General Vall d' Hebron, Barcelona, Spain.
Abstract
BACKGROUND/ OBJECTIVES: The pathogenesis of enteritis after abdominal radiotherapy (RT) is unknown, although changes in fecal microbiota may be involved. Prebiotics stimulate the proliferation of Lactobacillus spp and Bifidobacterium spp, and this may have positive effects on the intestinal mucosa during abdominal RT. SUBJECTS/ METHODS: We performed a randomized, double-blind, placebo-controlled trial involving patients with gynecological cancer who received abdominal RT after surgery. Patients were randomized to receive prebiotics or placebo. The prebiotic group received a mixture of fiber (50 inulin and 50% fructo-oligosaccharide), and the placebo group received 6 g of maltodextrin twice daily from 1 week before to 3 weeks after RT. The number of bowel movements and stool consistency was recorded daily. Diarrhea was evaluated according to the Common Toxicity Criteria of the National Cancer Institute. Stool consistency was assessed using the 7-point Bristol scale. Patients' quality-of-life was evaluated at baseline and at completion of RT using the EORTC-QLQ-C30 (European Organization for Research and Treatment of Cancer quality-of-life Questionnaire C30) test. RESULTS:Thirty-eight women with a mean age of 60.3±11.8 years participated in the study. Both groups (prebiotic (n=20) and placebo (n=18)) were comparable in their baseline characteristics. The number of bowel movements per month increased in both groups during RT. The number of bowel movements per day increased in both groups. The number of days with watery stool (Bristol score 7) was lower in the prebiotic group (3.3±4.4 to 2.2±1.6) than in the placebo group (P=0.08). With respect to quality-of-life, the symptoms with the highest score in the placebo group were insomnia at baseline and diarrhea toward the end of the treatment. In the prebiotic group, insomnia was the symptom with the highest score at both assessments, although the differences were not statistically significant. CONCLUSIONS: Prebiotics can improve the consistency of stools in gynecologic cancer patients on RT. This finding could have important implications in the quality-of-life of these patients during treatment.
RCT Entities:
BACKGROUND/ OBJECTIVES: The pathogenesis of enteritis after abdominal radiotherapy (RT) is unknown, although changes in fecal microbiota may be involved. Prebiotics stimulate the proliferation of Lactobacillus spp and Bifidobacterium spp, and this may have positive effects on the intestinal mucosa during abdominal RT. SUBJECTS/ METHODS: We performed a randomized, double-blind, placebo-controlled trial involving patients with gynecological cancer who received abdominal RT after surgery. Patients were randomized to receive prebiotics or placebo. The prebiotic group received a mixture of fiber (50 inulin and 50% fructo-oligosaccharide), and the placebo group received 6 g of maltodextrin twice daily from 1 week before to 3 weeks after RT. The number of bowel movements and stool consistency was recorded daily. Diarrhea was evaluated according to the Common Toxicity Criteria of the National Cancer Institute. Stool consistency was assessed using the 7-point Bristol scale. Patients' quality-of-life was evaluated at baseline and at completion of RT using the EORTC-QLQ-C30 (European Organization for Research and Treatment of Cancer quality-of-life Questionnaire C30) test. RESULTS: Thirty-eight women with a mean age of 60.3±11.8 years participated in the study. Both groups (prebiotic (n=20) and placebo (n=18)) were comparable in their baseline characteristics. The number of bowel movements per month increased in both groups during RT. The number of bowel movements per day increased in both groups. The number of days with watery stool (Bristol score 7) was lower in the prebiotic group (3.3±4.4 to 2.2±1.6) than in the placebo group (P=0.08). With respect to quality-of-life, the symptoms with the highest score in the placebo group were insomnia at baseline and diarrhea toward the end of the treatment. In the prebiotic group, insomnia was the symptom with the highest score at both assessments, although the differences were not statistically significant. CONCLUSIONS: Prebiotics can improve the consistency of stools in gynecologic cancerpatients on RT. This finding could have important implications in the quality-of-life of these patients during treatment.
Authors: P Delia; G Sansotta; V Donato; P Frosina; G Messina; C De Renzis; G Famularo Journal: World J Gastroenterol Date: 2007-02-14 Impact factor: 5.742
Authors: Rachel J Gibson; Dorothy M K Keefe; Rajesh V Lalla; Emma Bateman; Nicole Blijlevens; Margot Fijlstra; Emily E King; Andrea M Stringer; Walter J F M van der Velden; Roger Yazbeck; Sharon Elad; Joanne M Bowen Journal: Support Care Cancer Date: 2012-11-10 Impact factor: 3.603
Authors: P García-Peris; C Velasco; M A Lozano; Y Moreno; L Paron; C de la Cuerda; I Bretón; M Camblor; J García-Hernández; F Guarner; M Hernández Journal: Nutr Hosp Date: 2012 Nov-Dec Impact factor: 1.057
Authors: Alfonso Vidal-Casariego; Alicia Calleja-Fernández; Juan José Ortiz de Urbina-González; Isidoro Cano-Rodríguez; Fernando Cordido; María D Ballesteros-Pomar Journal: JPEN J Parenter Enteral Nutr Date: 2013-03-07 Impact factor: 4.016
Authors: Andrea Hille; Emine Schmidt-Giese; Robert M Hermann; Markus K A Herrmann; Margret Rave-Fränk; Markus Schirmer; Hans Christiansen; Clemens F Hess; Giuliano Ramadori Journal: Scand J Gastroenterol Date: 2008-01 Impact factor: 2.423
Authors: Jordi Giralt; José Perez Regadera; Ramona Verges; Jesus Romero; Isabel de la Fuente; Albert Biete; Jesús Villoria; Jose Maria Cobo; Francisco Guarner Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-19 Impact factor: 7.038
Authors: Joanne M Bowen; Rachel J Gibson; Janet K Coller; Nicole Blijlevens; Paolo Bossi; Noor Al-Dasooqi; Emma H Bateman; Karen Chiang; Charlotte de Mooij; Bronwen Mayo; Andrea M Stringer; Wim Tissing; Hannah R Wardill; Ysabella Z A van Sebille; Vinisha Ranna; Anusha Vaddi; Dorothy Mk Keefe; Rajesh V Lalla; Karis Kin Fong Cheng; Sharon Elad Journal: Support Care Cancer Date: 2019-07-08 Impact factor: 3.603
Authors: Selina E Eaton; Justyna Kaczmarek; Daanish Mahmood; Anna M McDiarmid; Alya N Norarfan; Erin G Scott; Chee Kin Then; Hailey Y Tsui; Anne E Kiltie Journal: Br J Cancer Date: 2022-09-29 Impact factor: 9.075
Authors: Taylor H Allenby; Megan L Crenshaw; Katlynn Mathis; Colin E Champ; Nicole L Simone; Kathryn H Schmitz; Leila T Tchelebi; Nicholas G Zaorsky Journal: Tech Innov Patient Support Radiat Oncol Date: 2020-09-14
Authors: Brynn A Hollingsworth; David R Cassatt; Andrea L DiCarlo; Carmen I Rios; Merriline M Satyamitra; Thomas A Winters; Lanyn P Taliaferro Journal: Front Pharmacol Date: 2021-05-18 Impact factor: 5.810
Authors: Theresa A Lawrie; John T Green; Mark Beresford; Linda Wedlake; Sorrel Burden; Susan E Davidson; Simon Lal; Caroline C Henson; H Jervoise N Andreyev Journal: Cochrane Database Syst Rev Date: 2018-01-23
Authors: Reihaneh Mazraeh; Fatemeh Azizi-Soleiman; Seyed Mohammad Hosein Mousavi Jazayeri; Seyyed Mohammad Ali Noori Journal: Pak J Med Sci Date: 2019 Mar-Apr Impact factor: 1.088